|
|
News Breaks | | | | January 8, 2013 | | 13:43 EDT |  | JAZZ | Jazz Pharma sees 2012 revenue to meet or exceed prior view of $575M-$585M
Consensus $592.91M. In presentation slides for the JPMorgan Global Healthcare Conference, Jazz Pharmaceuticals stated, "The company currently expects that, for the year ended December 31, 2012, reported total revenues will meet or exceed the guidance range provided on November 8, 2012. Guidance includes EUSA Pharma contribution from June 12, 2012 and Azur Pharma contribution from January 18, 2012, and excludes the Women’s Health business, which is now accounted for as discontinued operations." | |
|
News For JAZZ From The Last 14 Days Check below for free stories on JAZZ the last two weeks. |
|
|
| May 20, 2013 | | 11:18 EDT |  | JAZZ | High option volume stocks: JASO QUIK FWLT NM JAZZ
 Subscribe for More Information | |
|
|
|
|
|
|
